Zydus Lifesciences (NSE: ZYDUSLIFE) – Detailed Fundamental Screener & Price Target

Zydus Lifesciences pharmaceutical manufacturing plant

Investment Rating: Bullish (Quality Large-Cap Pharma Stock)

Zydus Lifesciences is one of India’s leading pharmaceutical companies with a diversified presence across generics, specialty medicines, vaccines, biologics, consumer wellness, and contract manufacturing. The company has built a strong global footprint, particularly in the US, India, Latin America, Europe, and emerging markets.

FY26 was another strong year:

Revenue: ₹27,148 crore (up ~17% YoY)
Q4 Revenue Growth: 16% YoY
EBITDA Growth: 20% YoY
Net Profit Growth: 15% YoY
EBITDA margin improved to 33.7%, reflecting better operating leverage and product mix.

Fundamental Screener

Parameter	Analysis	Rating
Business Quality	Diversified global pharma business	⭐⭐⭐⭐⭐
Revenue Growth	Strong	⭐⭐⭐⭐⭐
Profit Growth	Strong	⭐⭐⭐⭐☆
ROE	Healthy	⭐⭐⭐⭐☆
ROCE	Excellent	⭐⭐⭐⭐⭐
Operating Margin	Industry-leading	⭐⭐⭐⭐⭐
Debt	Low debt	⭐⭐⭐⭐⭐
Cash Flow	Strong	⭐⭐⭐⭐⭐
R&D Capability	Excellent	⭐⭐⭐⭐⭐
Promoter Quality	High	⭐⭐⭐⭐⭐
Institutional Holding	Strong	⭐⭐⭐⭐☆

Overall Fundamental Score: 9.4 / 10

Zydus Option Traders Corner

Leading Pharma Stock Bullish Segemnt for Option Buyers
Must Watch Those Sector Stocks Like Sun pharma,Biocon, Torrentpharma,Mankind, Lupin
Zydus Moving Vary Fast Charting so option Buyers got high Premium in Call option
But Everytime consolidate and sustain in Support then Move Forward is Better Price in High Price.

Business Segments

💊 Formulations

India branded formulations
US generic medicines
Europe and emerging markets

🧬 Specialty & Biologics

Biosimilars
Oncology
Autoimmune therapies
Specialty medicines

💉 Vaccines

Global vaccine portfolio
Innovation-led pipeline

🧪 API Business

Active Pharmaceutical Ingredients
Vertical integration
Export opportunities

🌿 Consumer Wellness

Nutraceuticals
OTC healthcare
Wellness products

Key Growth Drivers

1. Strong US Business

The US remains Zydus’ largest overseas market, supported by:

New generic launches
Complex injectables
Specialty products
First-to-file opportunities

2. Innovation & R&D

The company invests around 8–9% of revenue in research and development, supporting:

Biosimilars
Novel drug delivery
Specialty medicines
Complex generics
Vaccines.

3. India Formulations

Domestic branded business continues to benefit from:

Chronic therapies
Cardiology
Diabetes
Gastroenterology
Women’s healthcare

4. Specialty Medicine Expansion

Higher-margin specialty products are expected to gradually offset pricing pressure in traditional generics.

5. Strong Balance Sheet

Healthy cash generation
Low leverage
Capacity to fund acquisitions and innovation
Continued investment in manufacturing

Zydus Lifesciences Share Price

Competitive Advantages

✅ Diversified global revenue base

✅ Strong US presence

✅ Robust R&D pipeline

✅ Multiple USFDA-approved manufacturing plants

✅ Strong domestic pharmaceutical franchise

✅ Healthy operating margins

Risks

US generic pricing pressure
Regulatory observations from overseas agencies
Patent litigation risks
Currency fluctuations
Elevated R&D spending may temporarily affect margins as the company transitions toward specialty products.

Financial Outlook

Management continues to focus on:

High-value product launches
Biosimilar expansion
Specialty medicines
Global acquisitions
Sustainable margin improvement

Revenue growth is expected to remain in the low-to-mid teens over the next few years, supported by pipeline execution and international expansion.

Technical View

Trend: Bullish

Strong long-term uptrend
Positive institutional participation
Higher highs and higher lows on the weekly chart
Best accumulated on corrections rather than after sharp rallies

Price Target (Scenario-Based)

Time Horizon	Target Price
12 Months	₹1,200 – ₹1,300
2 Years	₹1,450 – ₹1,650
3 Years	₹1,700 – ₹2,000
5 Years	₹2,300 – ₹2,800
2030 (Bull Case)	₹3,000 – ₹3,800